We are live on ! Find out more
BHVN

Biohaven Pharmaceutical Holding Company Ltd.
BHVN

Delisted

BHVN was delisted on the 3rd of October, 2022.

Back to rankings

2 hedge funds and large institutions have $28.7M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

21% less capital invested

Capital invested by funds: $36.2M → $28.7M (-$7.52M)

33% less funds holding

Funds holding: 3 → 2 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.03%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
–
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KCM
Knoll Capital Management
Florida
+$1.87M

Top Sellers

Rank Fund Capital Flow
1
BHCM
Brevan Howard Capital Management
Jersey
-$326K
Name Holding Trade Value Shares
Change 		Change in
Stake
KCM
1
Knoll Capital Management
Florida
$28.4M +$1.87M +50,000 +7%
BC
2
Birchview Capital
Vermont
$275K – – –
BHCM
3
Brevan Howard Capital Management
Jersey
– -$326K -6,523 Closed

BHVN Hedge Fund Activity: Q4 2024 in Review

2 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q4 2024, worth a combined $28.7M — down 21% from $36.2M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of BHVN and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was Knoll Capital Management, adding an estimated $1.87M. The largest seller was Brevan Howard Capital Management, exiting entirely with an estimated $326K sold.

  • 2 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q4 2024, down from 3 in Q3 2024.
  • Funds reported $28.7M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q4 2024, down 21% quarter-over-quarter.
  • 0 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q4 2024 and 1 closed out, a net change of -1 holder.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q4 2024 was Knoll Capital Management, an estimated $1.87M added.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q4 2024 was Brevan Howard Capital Management, an estimated $326K sold.

Based on aggregated 13F filings for Q4 2024.